Application of Carbasalate Calcium in the Preparation of Drugs for Treating Hydrocephalus

Abstract

The present invention discloses the application of carbasalate calcium in the preparation of a medicament for treating hydrocephalus, belonging to the technical field of medicaments for treating hydrocephalus. The application of carbasalate calcium in the preparation of a medicament for treating hydrocephalus, wherein the medicament uses carbasalate calcium as the sole or main active ingredient. The present invention discovers for the first time the effect of carbasalate calcium in treating hydrocephalus, which can significantly reduce the area of the fourth ventricle of zebrafish in the hydrocephalus model, and significantly increase the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish in the hydrocephalus model; the experimental data provided by the present invention shows that carbasalate calcium has great application prospects in the treatment of hydrocephalus, provides an effective candidate medicament for reducing the treatment pain of hydrocephalus patients and reducing the treatment risk and cost; and broadens the scope of action of carbasalate calcium.

Description

Technical Field

[0001] The present invention relates to the technical field of drugs for the treatment of hydrocephalus, and in particular to the application of calcium carbaspirin in the preparation of drugs for the treatment of hydrocephalus. Background Art

[0002] Hydrocephalus is a condition in which there is abnormal accumulation of cerebrospinal fluid (CSF) in the intracranial cavity, usually caused by disorders in CSF circulation, absorption, or excessive secretion. According to the causes, hydrocephalus is mainly divided into two major categories: obstructive hydrocephalus and communicating hydrocephalus. Obstructive hydrocephalus is caused by obstruction of the CSF flow path, which can be due to congenital defects (such as Chiari malformation), tumors, infections (such as meningitis), hemorrhage (such as blood clots after subarachnoid hemorrhage), or other inflammatory diseases. The obstruction may occur at a certain site within the ventricles, such as the interventricular foramina or the channels leading from the ventricles to the subarachnoid space. Communicating hydrocephalus is not caused by physical obstruction of the CSF flow path, but by impaired absorption leading to CSF accumulation, which may be due to meningitis, head trauma, after treatment of certain types of brain tumors (such as radiotherapy), or decreased CSF absorption ability during the natural aging process. In addition, hydrocephalus may also be associated with genetic factors, congenital defects, or certain disease states.

[0003] Hydrocephalus can occur at any age, from newborns (infantile hydrocephalus) to the elderly. Existing statistical data show that in children, the incidence of hydrocephalus is approximately 1‰, and in the elderly population, the incidence is approximately 2‰. Hydrocephalus may lead to increased intracranial pressure, causing a series of neurological symptoms and signs, and the specific symptoms vary depending on the patient's age, cause, and severity of the condition. Common symptoms include headache, vomiting, papilledema (leading to vision problems), difficulty walking, cognitive impairment, and abnormal enlargement of the head circumference in children.

[0004] Traditional methods for the treatment of hydrocephalus mainly include the following: 1) Shunt surgery, which is the most common treatment method. Through surgical operation, a catheter (shunt tube) is placed inside or outside the ventricle of the brain to drain excessive cerebrospinal fluid to other parts of the body, usually the abdominal cavity (known as ventriculoperitoneal shunt), and sometimes it is also drained to the atrium or thoracic cavity. A valve is installed on the shunt tube to adjust the flow rate of cerebrospinal fluid to maintain normal intracranial pressure. 2) Endoscopic surgery. With the development of neuroendoscopic technology, for certain types of obstructive hydrocephalus, especially hydrocephalus caused by stenosis or obstruction, endoscopic third ventriculostomy (ETV) or endoscopic choroid plexus coagulation can be used for treatment. The ETV operation is to create a small hole at the bottom of the third ventricle through an endoscope to allow cerebrospinal fluid to directly flow into the subarachnoid space, thereby restoring the normal circulation of cerebrospinal fluid. 3) Drug treatment. Although drugs cannot cure hydrocephalus, in some cases, such as mild or transient hydrocephalus, or as an adjuvant treatment for surgery, drugs may be used to reduce the production of cerebrospinal fluid or help control the symptoms of patients. Currently, the commonly used drugs are diuretics.

[0005] There are certain risks and complications in the treatment methods of shunt surgery and endoscopic surgery. The complications include infection, catheter blockage, and over-drainage, etc. Currently, there is no drug approved by the National Medical Products Administration for the treatment of human hydrocephalus in clinical practice.

[0006] The main components of carbaspirin calcium are aspirin and calcium salts. It combines the antipyretic, analgesic, and anti-inflammatory effects of aspirin and the calcium supplement function. Clinically, it is mainly used for the fever caused by common cold or influenza, and also for relieving mild to moderate pain, such as headache, joint pain, migraine, toothache, muscle pain, neuralgia, and dysmenorrhea. Summary of the Invention

[0007] The purpose of the present invention is to provide the application of carbaspirin calcium in the preparation of drugs for the treatment of hydrocephalus, so as to solve the problem that currently hydrocephalus can only be treated by expensive surgeries with high risks of infection and complications, and to provide an effective candidate drug for the treatment of hydrocephalus, thereby reducing the treatment pain of patients and lowering the treatment risks and costs.

[0008] To achieve the above purpose, the present invention provides the application of carbaspirin calcium in the preparation of drugs for the treatment of hydrocephalus, and the drug uses carbaspirin calcium as the sole or main active ingredient.

[0009] Preferably, the drug further includes a pharmaceutically acceptable carrier.

[0010] Preferably, the effective dosage of carbaspirin calcium is 75 - 1000 mg / day.

[0011] Preferably, the effective dosage of carbaspirin calcium is 150 - 500 mg / day.

[0012] Preferably, the carbasalate calcium is administered orally when treating hydrocephalus.

[0013] The potential therapeutic target of carbasalate calcium for hydrocephalus is mmp9.

[0014] The present invention uses a zebrafish hydrocephalus model to screen out an active compound - carbasalate calcium, which can significantly reduce the area of the fourth ventricle of zebrafish with hydrocephalus, and thus can be used for preventing and / or treating zebrafish hydrocephalus.

[0015] Therefore, the application of carbasalate calcium provided by the present invention in the preparation of drugs for treating hydrocephalus has the following specific technical effects:

[0016] (1) The present invention discovers for the first time the effect of carbasalate calcium in treating hydrocephalus, which can significantly reduce the area of the fourth ventricle of zebrafish in the hydrocephalus model, and significantly improve the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish in the hydrocephalus model;

[0017] (2) The experimental data provided by the present invention show that carbasalate calcium has great application prospects in the treatment of hydrocephalus, providing an effective candidate drug for reducing the treatment pain, treatment risk and cost of hydrocephalus patients; and broadening the scope of action of carbasalate calcium.

[0018] The technical solution of the present invention will be further described in detail below through the accompanying drawings and examples. Description of the Drawings

[0019] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for the description of the embodiments of the present invention will be briefly introduced below. Obviously, the accompanying drawings in the following description are only some embodiments of the present invention, and those of ordinary skill in the art can also obtain other accompanying drawings based on these drawings without creative efforts.

[0020] Figure 1 It is a schematic diagram of the experimental process of Example 1 of the present invention;

[0021] Figure 2 It is the statistical result of the swimming distance of zebrafish larvae in different treatment groups of Example 1 of the present invention developed to 4 dpf;

[0022] Figure 3 It is the statistical result of the swimming speed of zebrafish larvae in different treatment groups of Example 1 of the present invention developed to 4 dpf;

[0023] Figure 4 It is the statistical result of the swimming time of zebrafish larvae in different treatment groups of Example 1 of the present invention developed to 4 dpf;

[0024] Figure 5 Rotation movement frequencies of zebrafish larvae in different treatment groups at 4 dpf in Example 1 of the present invention;

[0025] Figure 6 Statistical results of swimming distances of zebrafish larvae in different treatment groups at 4 dpf in Example 2 of the present invention;

[0026] Figure 7 Statistical results of swimming speeds of zebrafish larvae in different treatment groups at 4 dpf in Example 2 of the present invention;

[0027] Figure 8 Statistical results of swimming times of zebrafish larvae in different treatment groups at 4 dpf in Example 2 of the present invention;

[0028] Figure 9 Rotation movement frequencies of zebrafish larvae in different treatment groups at 4 dpf in Example 2 of the present invention;

[0029] Figure 10 Statistical results of swimming distances of zebrafish larvae of the blank control group, hydrocephalus group, hydrocephalus + carbaspirin calcium group, and carbaspirin calcium group at 4 dpf in Example 2 of the present invention;

[0030] Figure 11 Statistical results of swimming speeds of zebrafish larvae of the blank control group, hydrocephalus group, hydrocephalus + carbaspirin calcium group, and carbaspirin calcium group at 4 dpf in Example 2 of the present invention;

[0031] Figure 12 Statistical results of swimming times of zebrafish larvae of the blank control group, hydrocephalus group, hydrocephalus + carbaspirin calcium group, and carbaspirin calcium group at 4 dpf in Example 2 of the present invention;

[0032] Figure 13 Statistical results of rotation movement frequencies of zebrafish larvae of the blank control group, hydrocephalus group, hydrocephalus + carbaspirin calcium group, and carbaspirin calcium group at 4 dpf in Example 2 of the present invention;

[0033] Figure 14 Schematic diagram of the experimental procedure in Example 3 of the present invention;

[0034] Figure 15 Photomicrographs of zebrafish larvae of the blank control group (A), hydrocephalus group (B), hydrocephalus + carbaspirin calcium group (C), and carbaspirin calcium group (D) under a stereomicroscope in Example 3 of the present invention;

[0035] Figure 16 Statistical results of the fourth ventricle areas of zebrafish larvae of the blank control group, hydrocephalus group, hydrocephalus + carbaspirin calcium group, and carbaspirin calcium group at 72 hpf in Example 3 of the present invention;

[0036] Figure 17 Statistics results of the number of apoptotic cells in the fourth ventricle of zebrafish larvae at 72 hpf in the blank control group, hydrocephalus group, hydrocephalus + carbaspirin calcium group, and carbaspirin calcium group in Example 4 of the present invention;

[0037] Figure 18 Venn diagram generated from drug-related targets and hydrocephalus-related targets in Example 5 of the present invention;

[0038] Figure 19 Statistics results of the area of the fourth ventricle of zebrafish larvae at 72 hpf in the blank control group, hydrocephalus group, hydrocephalus + MMP-9-IN-9 group, and MMP-9-IN-9 group in Example 5 of the present invention;

[0039] Figure 20 Statistics results of the area of the fourth ventricle of zebrafish larvae at 72 hpf in the blank control group, hydrocephalus group, hydrocephalus + MMP-9-IN-1 group, and MMP-9-IN-1 group in Example 5 of the present invention. Detailed implementation manners

[0040] The technical solutions of the present invention will be further described below with reference to the drawings and examples.

[0041] In order to make the purpose, technical solutions and advantages of the present application clearer, more thorough and complete, the technical solutions of the present invention will be clearly and completely described below with reference to the drawings and examples. The following detailed descriptions are all descriptions of examples, aiming to provide further detailed descriptions of the present invention. Unless otherwise specified, all technical terms used in the present invention have the same meaning as commonly understood by those of ordinary skill in the technical field to which this application belongs.

[0042] The instrument equipment and reagent materials used in the examples are all obtained through commercial channels. Among them, the zebrafish larvae used are zebrafish embryos 6 h after birth; GRI977143 is purchased from Med Chem Express, carbaspirin calcium is purchased from MedChem Express, tricaine is purchased from SIGMA, PTU is purchased from SIGMA, AO stock solution is purchased from SIGMA, MS-222 is purchased from Med Chem Express, the stereomicroscope is purchased from Nikon, the zebrafish behavior recorder is purchased from Noldus, and the upright fluorescence microscope is purchased from OLYMPUS.

[0043] The experimental steps not described in detail in the examples are all conventional methods in the art.

[0044] Example 1

[0045] To investigate the effect of carbaspirin calcium on hydrocephalus in zebrafish larvae, the flow diagram is as Figure 1 shown, and the specific steps are as follows:

[0046] (1) Preparation of zebrafish larvae

[0047] Wild-type zebrafish are all from the Chinese Zebrafish Resource Center and are routinely maintained at 28 ± 0.5 °C under a 14 h light / 10 h dark cycle. After natural mating of wild-type zebrafish, zebrafish embryos are obtained. The obtained zebrafish embryos are washed and stored in E3 medium containing 2 mg / L methylene blue. During this period, the pH of the medium is maintained at 7.1, and the medium is changed daily.

[0048] E3 medium is composed of 5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 0.33 mM MgSO4.

[0049] (2) Experimental grouping and treatment

[0050] a. Blank control group: Zebrafish embryos at 6 h post-fertilization (6 hpf) are randomly transferred to a 24-well cell culture plate, with 15 zebrafish embryos per well. 1 mL of E3 medium is added so that all 6 hpf zebrafish embryos are in the E3 medium, and the medium is changed every 24 h.

[0051] b. Hydrocephalus group (Hydro): Zebrafish embryos at 6 hpf are randomly transferred to a 24-well cell culture plate, with 15 6 hpf zebrafish embryos per well. Then, a 5 μg / mL solution of GRI977143 is added so that all 6 hpf zebrafish embryos are exposed to the solution to induce hydrocephalus in zebrafish, and the GRI977143 solution is changed every 24 h.

[0052] c. Hydrocephalus + carbaspirin calcium group: Zebrafish embryos at 6 hpf are randomly transferred to a 24-well cell culture plate, with 15 6 hpf zebrafish embryos per well. Then, a 5 μg / mL solution of GRI977143 is added so that all 6 hpf zebrafish embryos are exposed to the solution. When the embryos develop to 24 h post-fertilization (24 hpf), a carbaspirin calcium solution is added to make the carbaspirin calcium concentrations 5 μM, 10 μM, and 20 μM respectively, and the concentration of the GRI977143 solution is kept at 5 μg / mL. The solution is changed every 24 h.

[0053] d. Carbaspirin calcium group: Zebrafish embryos at 6 hpf are randomly transferred to a 24-well cell culture plate, with 15 6 hpf zebrafish embryos per well. When the embryos develop to 24 h post-fertilization (24 hpf), a carbaspirin calcium solution is added to make the carbaspirin calcium concentrations 5 μM, 10 μM, and 20 μM respectively, and the solution is changed every 24 h.

[0054] (3) Zebrafish behavioral assay

[0055] When the embryos developed to 72 h (72 hpf), the zebrafish larvae in each group were subjected to zebrafish behavioral assay. Zebrafish embryos at the 4th day of development (4 dpf) were placed in a 48-well plate, one embryo per well, and 1000 μL of E3 culture medium was added. After adapting with a DanioVision (Noldus) recorder for 20 min, the light / dark cycle was recorded at 10 min / 10 min for 1 h. The statistical results of the swimming distance, swimming time, swimming speed, and rotational movement frequency of 4 dpf zebrafish larvae are respectively as Figures 2 - 5 shown. Compared with the blank control group, the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish in the hydrocephalus group were significantly decreased; after treatment with carbaspirin calcium (20 μM), the swimming distance, swimming time, swimming speed, and rotational movement frequency were significantly increased; compared with the blank control group, there were no significant differences in the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish in the group without induced hydrocephalus but with carbaspirin calcium added.

[0056] Example 2

[0057] To investigate the optimal treatment concentration of carbaspirin calcium solution, the specific steps are as follows:

[0058] (1) Preparation of zebrafish larvae was the same as in Example 1.

[0059] (2) Experimental grouping and treatment

[0060] a. Blank control group: Zebrafish embryos at 6 h (6 hpf) after birth were randomly transferred to a 24-well cell culture plate, 15 zebrafish embryos per well, and 1 mL of E3 culture medium was added to make all 6 hpf zebrafish embryos in the E3 culture medium, and the culture medium was changed every 24 h.

[0061] b. Hydrocephalus group (Hydro): Zebrafish embryos at 6 hpf were randomly transferred to a 24-well cell culture plate, 15 zebrafish embryos at 6 hpf per well, and then 5 μg / mL of GRI977143 solution was added to make all 6 hpf zebrafish embryos exposed to the solution to induce zebrafish hydrocephalus, and the GRI977143 solution was changed every 24 h.

[0062] c. Hydrocephalus + Carbasalate Calcium Group: Randomly transfer zebrafish embryos at 6 hpf to a 24-well cell culture plate, with 15 zebrafish embryos at 6 hpf in each well. Then add a 5 μg / mL solution of GRI977143 so that all zebrafish embryos at 6 hpf are exposed to the solution. When the embryos develop to 24 h (24 hpf), add a carbasalate calcium solution so that the concentrations of carbasalate calcium are 10 μM, 15 μM, 20 μM, and 25 μM respectively, and the concentration of the GRI977143 solution remains at 5 μg / mL. Replace the solution every 24 h.

[0063] d. Carbasalate Calcium Group: Randomly transfer zebrafish embryos at 6 hpf to a 24-well cell culture plate, with 15 zebrafish embryos at 6 hpf in each well. When the embryos develop to 24 h (24 hpf), add a carbasalate calcium solution so that the concentrations of carbasalate calcium are 10 μM, 15 μM, 20 μM, and 25 μM respectively. Replace the solution every 24 h.

[0064] (3) Zebrafish behavioral detection is the same as in Example 1.

[0065] The statistical results of the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish larvae at 4 dpf are shown respectively as Figures 6 - 9 follows. Compared with the blank control group, the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish in the hydrocephalus group decreased significantly; compared with the zebrafish larvae in the carbasalate calcium treatment groups with concentrations of 10 μM, 15 μM, and 25 μM, the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish larvae treated with 20 μM carbasalate calcium increased more significantly; compared with the blank control group, there were no significant differences in the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish in the group without induced hydrocephalus but added with 20 μM carbasalate calcium.

[0066] Therefore, the optimal dosage concentration of carbasalate calcium is 20 μM, and the statistical results of the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish larvae at the optimal dosage concentration of carbasalate calcium are shown respectively as Figures 10 - 13 follows.

[0067] Example 3

[0068] Use a stereomicroscope to image the zebrafish cerebral ventricle. The specific steps are as follows:

[0069] (1) Preparation of zebrafish larvae is the same as in Example 1.

[0070] (2) Experimental grouping and treatment were the same as in Example 2, except that the E3 culture medium was replaced with PTU solution. PTU (phenylthiourea) is a Tyr (tyrosinase) inhibitor that can inhibit the growth of melanin in zebrafish embryos, increase the optical transparency of zebrafish embryos, and facilitate the acquisition of better images under a microscope for research. The concentration of carbaspirin calcium in the hydrocephalus + carbaspirin calcium group and the carbaspirin calcium group was 20 μM.

[0071] (3) Zebrafish ventricle imaging

[0072] When the zebrafish embryos develop to 72h (72hpf), each group of embryos is embedded in low melting point agarose and set aside. After the stereo microscope is debugged, the zebrafish ventricle images are obtained respectively. The flow chart is as follows Figure 14 Some stereo microscope photos are shown in Figure 15 The size of the ventricles was measured using Image J software, and the statistical results of 13 replicates are shown in Figure 16 As shown, the fourth ventricle area of ​​zebrafish in the hydrocephalus group was significantly increased compared with the blank control group; after treatment with carbaspirin calcium, the fourth ventricle area was significantly restored; there was no significant difference in the fourth ventricle area of ​​zebrafish in the group without inducing hydrocephalus but adding carbaspirin calcium compared with the blank control group.

[0073] Embodiment 4

[0074] The number of apoptotic cells in the fourth ventricle of zebrafish was counted using an upright fluorescence microscope. The specific steps are as follows:

[0075] (1) The preparation of zebrafish fry is the same as in Example 1.

[0076] (2) Experimental grouping and treatment are the same as in Example 3.

[0077] (3) Statistical analysis of apoptotic cells in the fourth ventricle of zebrafish

[0078] Acridine orange (AO) is a staining agent used to identify apoptosis. Dilute the AO stock solution (1 mg / mL, prepared with pure water) at a ratio of 1:200 with E3 culture medium to make its final concentration 5 μg / mL. Randomly select 12 juvenile fish (72 hpf) from different treatment groups, rinse them with E3 culture medium to remove residual exposure solution, place them in a centrifuge tube, then add 1 mL of the diluted AO dye, incubate at 28 ± 0.5 °C for 20 minutes, and keep in the dark environment to prevent fluorescence quenching. After incubation, wash with E3 solution for 5 minutes to remove the AO dye that has not entered the cells, and then anesthetize these juvenile fish with 0.01% MS-222 for 3 minutes. Take pictures of apoptotic cells in zebrafish with an upright fluorescence microscope (filter: GFP, wavelength: 470 ± 20 nm). Use Imaris to count the number of apoptotic cells in the fourth ventricle of each juvenile fish. The statistical results of 12 replicates are as Figure 17 shown. Compared with the blank control group, the number of apoptotic cells in the fourth ventricle of zebrafish in the hydrocephalus group increased significantly; after treatment with carbaspirin calcium, the number of apoptotic cells decreased; compared with the blank control group, there was no significant difference in the number of apoptotic cells in the fourth ventricle of zebrafish in the group without induced hydrocephalus but with added carbaspirin calcium.

[0079] Example 5

[0080] The determination of potential therapeutic targets of carbaspirin calcium for hydrocephalus is as follows:

[0081] Use the keyword "Hydrocephalus" in GeneCards (https: / / www.genecards.org / ), OMIM (https: / / www.omim.org / ) and DisGeNET (https: / / disgenet.com / ) to search for hydrocephalus-related targets, integrate the search results of the three databases and remove duplicate gene targets to obtain hydrocephalus-related targets, and construct a hydrocephalus disease target library.

[0082] Send the juvenile fish samples of the blank control group and the hydrocephalus group to Biomarker Technologies Corporation for transcriptome sequencing analysis to obtain the differentially expressed genes between the blank control group and the hydrocephalus group, and construct a transcriptome target library.

[0083] The keywords "GRI977143" and "Carbasalatum calcicum" were used to retrieve drug-related targets in SwissTargetPrediction (http: / / swisstargetprediction.ch / index.php), PharmMapping (https: / / www.lilab-ecust.cn / pharmmapper / ), and Similarity ensemble approach (http: / / sea.bkslab.org / ). The search results of the three databases were integrated and duplicate gene targets were removed to obtain drug-related targets, and a GRI977143 target library and a carbasalate calcium target library were constructed.

[0084] By importing drug-related targets and hydrocephalus-related targets into the Venny 2.1.0 web platform (https: / / bioinfogp.cnb.csic.es / tools / venny / index.html), a Venn diagram was generated, as Figure 18 shown, and the intersection target was retrieved as mmp9.

[0085] Subsequently, mmp9 inhibitors were applied to zebrafish larvae to verify whether mmp9 is a therapeutic target of carbasalate calcium. The specific steps are as follows:

[0086] (1) The preparation of zebrafish larvae was the same as in Example 1.

[0087] (2) The experimental grouping and treatment were the same as in Example 2, with carbasalate calcium replaced by mmp9 inhibitors (MMP-9-IN-9, MMP-9-IN-1).

[0088] (3) Imaging of the zebrafish cerebral ventricle with a stereomicroscope was the same as in Example 3.

[0089] Compared with the blank control group, the area of the fourth ventricle in the hydrocephalus group of zebrafish increased significantly; after treatment with mmp inhibitors, the area of the fourth ventricle recovered significantly, as Figures 19 - 20 shown.

[0090] Therefore, the potential therapeutic target of carbasalate calcium is mmp9.

[0091] Therefore, the present invention discovers for the first time the role of carbaspirin calcium in the treatment of hydrocephalus, which can significantly reduce the area of the fourth ventricle of zebrafish in the hydrocephalus model, significantly increase the swimming distance, swimming time, swimming speed, and rotational movement frequency of zebrafish in the hydrocephalus model, and significantly reduce the number of apoptotic cells in the fourth ventricle of zebrafish in the hydrocephalus model; its potential therapeutic target is mmp9. The experimental data provided by the present invention show that carbaspirin calcium has great application prospects in the treatment of hydrocephalus, providing an effective candidate drug for reducing the treatment pain, treatment risk and cost of hydrocephalus patients; and broadening the scope of action of carbaspirin calcium.

[0092] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit them. Although the present invention has been described in detail with reference to the preferred embodiments, those of ordinary skill in the art should understand that they can still modify or equivalently replace the technical solutions of the present invention, and these modifications or equivalent replacements cannot make the modified technical solutions deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. The use of carbaspirin calcium in the preparation of a drug for treating hydrocephalus, characterized in that: The medicine uses carbaspirin calcium as the only or main active ingredient.

2. The use of carbaspirin calcium according to claim 1 in the preparation of a drug for treating hydrocephalus, characterized in that: The medicament further includes a pharmaceutically acceptable carrier.

3. The use of carbaspirin calcium according to claim 1 in preparing a drug for treating hydrocephalus, characterized in that: The effective dosage of carbaspirin calcium is 75-1000 mg / day.

4. The use of carbaspirin calcium according to claim 1 in the preparation of a drug for treating hydrocephalus, characterized in that: The effective dosage of carbaspirin calcium is 150-500 mg / day.

5. The use of carbaspirin calcium according to claim 1 in preparing a drug for treating hydrocephalus, characterized in that: The carbaspirin calcium is taken orally in the treatment of hydrocephalus.

Images